Condition: Asthma · Sponsor: GlaxoSmithKline
The aim of this study is to evaluate the efficacy of depemokimab administered as an adjunctive therapy, in participants with Type 2 asthma at risk of exacerbations compared to the guideline recommended standard of care (SoC).
This description comes directly from the study's public registry record.
US GSK Clinical Trials Call Center · 877-379-3718 · GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center · +44 (0) 20 89904466 · GSKClinicalSupportHD@gsk.com
Always discuss trial participation with your own doctor first.
| GSK Investigational Site | Newport Beach, California, United States | Recruiting |
| GSK Investigational Site | Aventura, Florida, United States | Recruiting |
| GSK Investigational Site | Kissimmee, Florida, United States | Recruiting |
| GSK Investigational Site | Miami, Florida, United States | Recruiting |
| GSK Investigational Site | Miami, Florida, United States | Recruiting |
| GSK Investigational Site | Miami, Florida, United States | Recruiting |
| GSK Investigational Site | Oklahoma City, Oklahoma, United States | Recruiting |
| GSK Investigational Site | Rapid City, South Dakota, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07456033